Opdivo Plus Chemo Provides Survival Benefit in Bladder Cancer Subtype
Immunotherapy with Opdivo plus cisplatin-based chemotherapy improved overall survival and progression-free survival in patients with unresectable or metastatic urothelial carcinoma.